Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

FUTU vs NMR: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

FUTU Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 7–3 Matrix Metrics)

FUTU Overall Winner 6-Pillar Tally: FUTU 4 – 1 NMR (1 Tie) Matrix Metrics: FUTU 7 – 3 NMR

As of Nov 17, 2026, Futu Holdings Limited (FUTU) is the stronger overall head-to-head candidate over Nomura Holdings, Inc (NMR) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). FUTU carries a Unified Composite Score of 47.3/100 (HOLD) at $86.89 (8.6x Forward P/E, 66.7% operating margin), whereas NMR carries 44.5/100 (HOLD) at $9.34 (12.7x Forward P/E, 25.1% operating margin).

  • Technical & Structure Timing Caution: FUTU is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 32.5); meanwhile NMR trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 45.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About FUTU vs NMR
FUTU NASDAQ Head-to-Head Winner
Futu Holdings Limited American Depositary Shares
Security Brokers, Dealers & Flotation Companies
$86.89
-5.14% 1D
Market Cap $13.4B
TTM Revenue $3.06B
Forward P/E 8.6x
Beta / 30D Vol 1.79β · 49% Vol
Unified Composite Score
47.3 / 100 HOLD
Tech 33.0 Fund 48.0 Flow 50.0 Mom 68.9
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -6.3%), weak momentum, RSI 33
RSI-14: 32.5 · SMA20: $98.46 · SMA50: $105.72
NMR NYSE
Nomura Holdings, Inc
Security Brokers, Dealers & Flotation Companies
$9.34
-1.68% 1D
Market Cap $28.3B
TTM Revenue $14.9B
Forward P/E 12.7x
Beta / 30D Vol 1.03β · 29% Vol
Unified Composite Score
44.5 / 100 HOLD
Tech 47.0 Fund 49.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 45
RSI-14: 45.5 · SMA20: $9.40 · SMA50: $9.68

6-Pillar Scorecard Institutional Category Breakdown (FUTU 4 – 1 NMR)

Columns: Metric · FUTU · NMR
1. Valuation Multiples FUTU
Forward P/E 8.6x 12.7x
Trailing P/E 9.5x 11.2x
PEG Ratio N/M 0.81x
EV / Revenue 4.4x 1.9x
2. Growth & Scale FUTU
Revenue Growth (YoY) +35.6% +17.9%
Earnings Growth (YoY) +43.0% +13.6%
TTM Revenue (USD) $3.06B $14.9B
Market Cap $13.4B $28.3B
3. Profitability & Quality FUTU
Gross Margin 94.1% 77.4%
Operating Margin 66.7% 25.1%
Net Profit Margin 46.2% 17.1%
Return on Equity (ROE) 30.5% 11.5%
4. Balance Sheet & Cash Flow FUTU
Cash Generation (TTM) N/A N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage $35.71 Book/Sh · 30.5% ROE $8.17 Book/Sh · 11.5% ROE
Dividend Yield None (0.00%) 3.34%
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 49.3% (20th %ile) 30.7% (<1st %ile)
Put/Call OI Skew Thin ADR Chain Thin ADR Chain
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Neutral
6. R&D & Supply-Chain Moat NMR
OpEx & R&D Intensity 27.4% of Rev ($838M) 52.3% of Rev ($7.77B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat High-Margin Pricing Power Moat Scale & Operating Efficiency Moat
Supply-Chain Role Capital Markets Operator Capital Markets Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: FUTU (7) vs NMR (3)
Institutional Metric FUTU NMR Criterion Row Edge
Market Capitalization
Scale
$13.4B $28.3B Larger Scale NMR
Trailing P/E Ratio
Valuation
9.5x 11.2x Lower Multiple FUTU
Forward P/E Ratio
Valuation
8.6x 12.7x Lower Multiple FUTU
Revenue Growth (YoY)
Growth
+35.6% +17.9% Higher Growth FUTU
Operating Margin (TTM)
Profitability
66.7% 25.1% Higher Margin FUTU
Net Profit Margin
Profitability
46.2% 17.1% Higher Margin FUTU
Return on Equity (ROE)
Capital Efficiency
30.5% 11.5% Higher ROE FUTU
52-Week Range Position
Momentum
6% ($80–$189) 61% ($7–$11) Stronger Trend NMR
Beta / 30D Volatility
Risk Regime
1.79β · 49% Vol 1.03β · 29% Vol Lower Realized Risk NMR
Unified Institutional Score
Composite Signal
47.3 / 100 (HOLD) 44.5 / 100 (HOLD) Higher Composite FUTU
Trailing 12M Revenue (USD)
Operating Scale
$3.06B $14.9B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
94.1% 77.4% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 4.4x EV/Rev 0.81x PEG · 1.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A ($35.71 Book/Sh · 30.5% ROE) N/A ($8.17 Book/Sh · 11.5% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon NMR +20.05 pp
FUTU: -17.64% · NMR: +2.41%
3M Horizon NMR +18.8 pp
FUTU: -20.59% · NMR: -1.79%
6M Horizon NMR +46.96 pp
FUTU: -30.21% · NMR: +16.75%
1Y Horizon NMR +73.97 pp
FUTU: -47.58% · NMR: +26.39%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on FUTU vs NMR. Trailing 12-month operating profitability (FUTU 66.7% vs NMR 25.1%) and valuation multiples (FUTU 8.6x vs NMR 12.7x Forward P/E) are benchmarked directly in Pillar 4 below.

FUTU ADR TTM Benchmark FX-Normalized USD
TTM Revenue$3.06B
Gross Margin94.1%
Op. Margin66.7%
ROE / Fwd P/E30.5% · 8.6x
NMR ADR TTM Benchmark FX-Normalized USD
TTM Revenue$14.9B
Gross Margin77.4%
Op. Margin25.1%
ROE / Fwd P/E11.5% · 12.7x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
FUTU UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 49.3%
IV Percentile 20th %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact FUTU Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
NMR UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 30.7%
IV Percentile <1st %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact NMR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
FUTU Moat Profile High-Margin Pricing Power Moat
Capital Markets Operator
Competes within the Capital Markets value chain with $13.4B market capitalization and 66.7% operating margin.
OpEx & R&D Reinvestment 27.4% of Rev ($838M)
90D Engineering Disclosures 0 Published
NMR Moat Profile Scale & Operating Efficiency Moat
Capital Markets Operator
Competes within the Capital Markets value chain with $28.3B market capitalization and 25.1% operating margin.
OpEx & R&D Reinvestment 52.3% of Rev ($7.77B)
90D Engineering Disclosures 0 Published

Investor FAQ FUTU vs NMR Key Questions & Quantitative Answers

As of Nov 17, 2026, Futu Holdings Limited (FUTU) is the stronger overall head-to-head candidate over Nomura Holdings, Inc (NMR) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). FUTU carries a Unified Composite Score of 47.3/100 (HOLD) at $86.89 (8.6x Forward P/E, 66.7% operating margin), whereas NMR carries 44.5/100 (HOLD) at $9.34 (12.7x Forward P/E, 25.1% operating margin). Technical & Structure Timing Caution: FUTU is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 32.5); meanwhile NMR trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 45.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

FUTU leads the Growth & Scale pillar: FUTU posts +35.6% YoY revenue growth and +43.0% YoY earnings growth on $3.06B TTM revenue (94.1% gross margin, 66.7% operating margin), compared with NMR at +17.9% YoY revenue growth and +13.6% YoY earnings growth on $14.9B TTM revenue (77.4% gross margin, 25.1% operating margin). On trailing 12-month operating scale, FUTU generates $3.06B in USD-normalized revenue versus $14.9B for NMR. In operating R&D and SG&A reinvestment, FUTU deploys 27.4% of Rev ($838M) (0 90-day corporate R&D disclosures) versus 52.3% of Rev ($7.77B) (0 disclosures) for NMR.

FUTU screens cheaper on headline valuation multiples. FUTU trades at 8.6x Forward P/E, 9.5x Trailing P/E, N/M PEG, and 4.4x EV/Revenue (unreported cash flow margin), whereas NMR trades at 12.7x Forward P/E, 11.2x Trailing P/E, 0.81x PEG, and 1.9x EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against FUTU (30.5% ROE) versus NMR (11.5% ROE) capital efficiency.

In options market volatility and institutional positioning, FUTU carries 49.3% implied volatility (20th %ile, Compressed (<25th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.79β · 49% Vol realized risk). By comparison, NMR carries 30.7% implied volatility (<1st %ile, Compressed (<25th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.03β · 29% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.